The pharmaceutical firm GlaxoSmithKline has announced it will open a global vaccine research facility in Maryland, moving research operations from Philadelphia and Cambridge, Massachusetts.
The Rockville location will join other GSK vaccine R&D hubs in Rixensart, Belgium, and Siena, Italy. GSK said that research work at the facility would begin in September, and could involve as many as 1,000 jobs, including some 600 workers likely to be brought in from the existing labs.
GSK’s Rockville facility joins a number of biotech and pharmaceutical operations in the area, just outside Washington, DC. The maker of the only US-approved anthrax vaccine is located in Rockville, and AstraZeneca in 2014 announced it would expand its manufacturing facility in nearby Frederick, Maryland. All are within miles of federal agencies such as the National Institutes of Health and the Food and Drug Administration.